Head-and-neck squamous-cell carcinoma (HNSCC) — a frequent neoantigen-vaccine setting.
Log in here to read the desired article. French biotech Transgene said all 16 head and neck cancer patients treated with its personalized cancer vaccine TG4050 in a randomized Phase 1 trial remained disease-free after three years, while three of 16 patients in the control arm rel…
Transgene and NEC Corporation have reported sustained 100% three-year disease-free survival (DFS) among patients treated with the individualized neoantigen therapeutic vaccine TG4050 in the Phase 1 portion of a randomized Phase 1/2 trial in resected, locally advanced HPV-negative…
Researchers Ottensmeier, Delord, and Lalanne report on a randomized Phase I trial of a viral-based individualized neoantigen vaccine for patients with resected HNSCC. Designed as an adjuvant treatment to target microscopic residual disease, the vaccine is customized to each patient's specific tumor mutations rather than targeting a common antigen. This approach addresses the biological diversity of HNSCC and aims to reduce recurrence rates where standard therapies have limitations.
January 09, 2026 02:00 ET | Source: Transgene S.A. Transgene S.A. TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 potential as an individualized cancer immunotherapy Strasbourg, Franc…
A new review in Frontiers in Oncology outlines the rationale for combining personalized cancer vaccines with immune checkpoint inhibitors in head and neck squamous cell carcinoma (HNSCC). The authors highlight that while HNSCC presents challenges due to its complex tumor microenvironment and lack of actionable mutations, therapeutic vaccines can enhance innate and adaptive immune responses. This synthesis underscores the clinical momentum toward combination therapies to overcome resistance in this high-burden indication.